Pharma channel feed

Got­tlieb tack­les spec­u­la­tors, FDA trans­paren­cy and the R&D gold stan­dard in a last round of queries ahead of con­fir­ma­tion vote

9 years ago

Ot­su­ka gob­bles up more glob­al rights for Ake­bia’s vadadu­s­tat, chip­ping in to a pot now worth $2B-plus

9 years ago

Blitzed by tri­al fail­ures, On­coMed ax­es half its staff and re­trench­es around PhI drugs

9 years ago
R&D

With late-stage da­ta in on the CGRP mi­graine drug erenum­ab, No­var­tis and Am­gen re­work com­mer­cial­iza­tion pact

9 years ago

Marathon Phar­ma­ceu­ti­cals sig­nals it will wind down af­ter stir­ring a hor­net’s nest with $89,000 Duchenne treat­ment

9 years ago

Fac­ing a pay­er back­lash over stick­er shock, Bio­gen fields pos­i­tive da­ta on Spin­raza for chil­dren 2-12

9 years ago
R&D

J&J faces its sec­ond ri­val Rem­i­cade knock­off as FDA gives Mer­ck a shot at a $7B fran­chise

9 years ago

It’s of­fi­cial: Con­tro­ver­sial Marathon Phar­ma­ceu­ti­cals bows out at PhRMA in wake of price goug­ing con­tro­ver­sy

9 years ago

XBiotech shares crater as CHMP shud­ders at its ap­pli­ca­tion to sell Xilonix

9 years ago

Black box warn­ing? No wor­ries, Valeant bills Siliq as the ‘low-cost’ pso­ri­a­sis al­ter­na­tive to ri­vals from No­var­tis, Eli Lil­ly

9 years ago

Ver­nalis shares slide af­ter FDA turn thumbs down on their lat­est XR cold med

9 years ago

The list of the top 10 most ex­pen­sive drugs on the plan­et will soon have a new open­ing

9 years ago

Is Tesaro play­ing a pric­ing game with Ze­ju­la? Not at all, says the CEO. And here's why

9 years ago

That turn­around on new FDA drug ap­provals? We’re right on sched­ule

9 years ago

Ver­i­ly joins up with Duke, Stan­ford to en­list an army of con­sumers to put its next-gen sen­sor tech to the test — and in the pub­lic eye

9 years ago

No­var­tis ties up with the vir­tu­al biotech Parvus to try a new ap­proach on Type 1 di­a­betes

9 years ago
R&D

Re­port: Han­mi’s fail­ure to re­port pa­tient death in ol­mu­tinib study broke South Ko­rea’s med­ical laws

9 years ago
R&D

The UK is­n't giv­ing up on keep­ing the Eu­ro­pean Med­i­cines Agen­cy's HQ in Lon­don with­out a fight

9 years ago

Scoop: Juno re­cruits Sunil Agar­w­al as R&D chief, open­ing a Bay Area fa­cil­i­ty in re­search re­vamp

9 years ago

In a stun­ning set­back, FDA spurns Eli Lil­ly’s mar­ket­ing ap­pli­ca­tion for baric­i­tinib, de­mands more da­ta

9 years ago

New CEOs at Ax­o­vant, Des­tiny and Organo­vo mark a busy week for the biotech jobs scene

9 years ago
R&D
Peer Review

We don’t know when (ex­act­ly) Lil­ly will an­nounce the FDA’s baric­i­tinib de­ci­sion, but watch out for the loom­ing pric­ing squab­ble

9 years ago

Ed­i­tas’ ri­vals ap­peal a re­cent set­back on patent fight, map­ping a glob­al war for CRISPR su­prema­cy

9 years ago

Roche, Bio­gen hand­ing over $470M in cash to bag two drug pro­grams from Bris­tol-My­ers Squibb

9 years ago
First page Previous page 325326327328329330331 Next page Last page
A service from the Financial Times